{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stein A"],"funding":["Merck & Co., Inc. | MSD K.K.","Merck & Co., Inc. | MSD K.K."],"pagination":["4197-4204"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12705456"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(12)"],"pubmed_abstract":["Perioperative treatment strategies for HER2-positive esophagogastric adenocarcinoma remain suboptimal. Here in the open-label, phase 2 IKF/AIO PHERFLOT trial, we evaluated the safety and efficacy of adding pembrolizumab and trastuzumab to FLOT chemotherapy in patients with localized HER2-positive esophagogastric adenocarcinoma. The primary endpoints are the pathological complete response rate and the 2-year disease-free survival rate. Secondary endpoints include the R0 resection rate, feasibility and safety. Exploratory endpoints include clinical efficacy in molecularly defined subgroups. In this prespecified interim analysis, given the limited median follow-up period of 14.8 months, only one of the primary endpoints, the pathological complete response rate, and selected secondary endpoint"],"journal":["Nature medicine"],"pubmed_title":["Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial."],"pmcid":["PMC12705456"],"funding_grant_id":["–"],"pubmed_authors":["Cruz MS","Tintelnot J","Goekkurt E","Hofheinz RD","Goetze T","Siegler G","Lorenzen S","Broering T","Stein A","Thiele B","Moosmann N","Gruen B","Binder M","Muller C","Ettrich TJ","Pauligk C","Homann N","Al-Batran SE","Rempel V"],"additional_accession":[]},"is_claimable":false,"name":"Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.","description":"Perioperative treatment strategies for HER2-positive esophagogastric adenocarcinoma remain suboptimal. Here in the open-label, phase 2 IKF/AIO PHERFLOT trial, we evaluated the safety and efficacy of adding pembrolizumab and trastuzumab to FLOT chemotherapy in patients with localized HER2-positive esophagogastric adenocarcinoma. The primary endpoints are the pathological complete response rate and the 2-year disease-free survival rate. Secondary endpoints include the R0 resection rate, feasibility and safety. Exploratory endpoints include clinical efficacy in molecularly defined subgroups. In this prespecified interim analysis, given the limited median follow-up period of 14.8 months, only one of the primary endpoints, the pathological complete response rate, and selected secondary endpoint","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T15:56:42.808Z","creation":"2026-06-02T03:10:29.535Z"},"accession":"S-EPMC12705456","cross_references":{"pubmed":["41109919"],"doi":["10.1038/s41591-025-03979-y"]}}